ACR Share Price Performance
AU$0.01
-0.00 (-33.33%)
88.9% undervalued intrinsic discount
AU$0.09
Fair Value
Price AU$0.01
AnalystConsensusTarget AU$0.09
Fair ValueAU$0.09
Share Pricen/a
Acrux Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
ACR Community Narratives
AN
Fair Value
·Fair Value AU$0.09 88.9% undervalued intrinsic discount
New Product Launches Including Cone 75% Will Expand Market Presence
1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
New Product Launches Including Cone 75% Will Expand Market Presence
Key Takeaways Expansion into niche markets and strategic licensing agreements are aimed at enhancing net margins and diversifying revenue streams. Product pipeline growth coupled with a strong financial position supports sustained long-term revenue and earnings growth.Read more
AN
AU$0.09
88.9% undervalued intrinsic discount
Fair Value
Profit Margin
44.47%
Future PE
4.32x
Price in 2028
AU$0.11
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
New Product Launches Including Cone 75% Will Expand Market Presence
Fair Value: AU$0.09 88.9% undervalued intrinsic discount
16 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Acrux Limited Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.001
- 100.00%
- -9.16%
- 64.8%
About ACR
- Founded
- 1998
- Employees
- n/a
- CEO
- WebsiteView website
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.
